Topical Ophthalmic AGN-195263 for the Treatment of Evaporative Dry Eye

Summary

The objectives of this study are twofold •To evaluate the safety and efficacy of 0.1% AGN-195263 administered twice daily compared to its vehicle in patients with evaporative dry eye (EDE) •To evaluate the systemic pharmacokinetics of 0.1% AGN-195263 administered twice daily in patients with EDE

Timeline

Start

2016-12-13

Primary completion

2017-06-13

Completion

2017-06-13

Drugs

Indications